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Maintaining the physiological pH of interstitial fluid is crucial for normal cellular functions. In disease states, tissue
acidosis is a common pathologic change causing abnormal activation of acid-sensing ion channels (ASICs), which
according to cumulative evidence, significantly contributes to inflammation, mitochondrial dysfunction, and other
pathologic mechanisms (i.e., pain, stroke, and psychiatric conditions). Thus, it has become increasingly clear that ASICs
are critical in the progression of neurologic diseases. This review is focused on the importance of ASICs as potential
therapeutic targets in combating neurologic diseases.
Keywords: Acid sensing ionic channels, Neurologic diseases, Pathophysiology, NeurodegenerationUnder normal physiologic conditions, intra- and extra-
cellular pH is maintained between 7.3-7.0. Increased
neuronal excitability alters pH to activate various recep-
tors and ion channels in cell membranes, including a
variety of voltage-gated and ligand-gated ion channels
[1, 2]. It has recently been shown that acid-sensing ion
channels (ASICs) first cloned by Waldmann and col-
leagues [3] are activated in response to diminished extra-
cellular pH [4]. However, the functional roles of ASICs
in peripheral and central components of the nervous
system remain unclear.
Neurodegenerative diseases, such as Parkinson’s disease,
Huntington’s disease, and Alzheimer’s disease, are not cur-
able at present. Although animal models of such condi-
tions have been utilized to develop new therapeutic
strategies, effective treatments have been elusive. Clinical
trial and animal experimentation outcomes suggest that
Ca2+ overload, mitochondrial dysfunction, oxidative stress,
energy metabolism, and acidosis are involved in neurode-
generative processes. Consequently, ASICs may be pivotal
in the pathophysiology of these disorders.
Basic characteristics of ASICs
ASICs are ligand-gated cation channels activated by extra-
cellular H+ and are widely distributed in mammalian* Correspondence: liucf@suda.edu.cn
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unless otherwise stated.central and peripheral nervous systems. As members of
the degenerin and epithelial Na+ channel (DEG/ENaC)
ion channel superfamily, displaying high Na+ permeability
and sensitivity to amiloride blockade (with brief exposure),
ASICs are composed of two hydrophobic transmembrane
domains, short N- and C- termini, and a large extracellular
loop (ECD) spanning the two hydrophobic domains [5–7].
The ECD harbors a so-called “acidic pocket” region that is
responsible for acid-dependent gating, desensitization, and
response to extracellular modulators [8]. This acidic pocket
contains several pairs of acidic amino acids, is situated at
the interface between two subunits, and is considered one
of the ASIC pH sensors. Cations may gain access via lateral
fenestrations in the wrist region and then move into a
broad extracellular vestibule [8, 9]. The crystal structure of
chicken ASIC1 incorporates a trimeric channel com-
plex, marked by three radial subunits and a central ion
pore [10]. Discovery of the ASIC crystal structure pro-
vided insight into inherent mechanisms of channel
depolarization, inactivation, and modulation. The three-
dimensional ECD consists of 12 b-sheets and 7 a-helices
[9]. Two long a-helices form the transmembrane domains,
which line the ion pore [9].
ASICs were first identified in the nervous system and
cloned 14 years ago [11]. In mammals, there are six dis-
tinct ASIC subunits (ASIC1a, ASIC1b, ASIC2a, ASIC2b,
ASIC3, and ASIC4) encoded by four different genes
(ACCN1–4) (Table 1) [12]. These subunits form functional
ion channels as dimers or heteropolymers, and differings is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Properties and distributions of ASIC subunits
ASIC subtype pH sensitivity Distribution
ASIC1a 5.8–6.8 CNS and PNS
ASIC1b 6.1–6.2 PNS
ASIC2a 4.5–4.9 CNS and PNS
ASIC2b not applicable CNS and PNS
ASIC3 6.4–6.6 PNS
ASIC4 not applicable CNS and PNS
Liu et al. Translational Neurodegeneration  (2015) 4:10 Page 2 of 8channels vary in activation conditions, ion selectivity, kin-
etics, and distributions.
ASICs are activated by falls in extracellular pH, par-
ticularly tissue acidosis (Fig. 1). Whole-cell patch clamp
recording studies show that an increase in intracellular
Ca2+ due to cerebral ischemia may be attenuated by the
nonspecific Na+ channel inhibitor amiloride or the spe-
cific ASIC1a inhibitor PcTx1, both of which prevent tis-
sue damage (Fig. 2) [13]. Other studies indicate that
ASIC1a-mediated Ca2+ overload contributes to ischemic
nerve cell death and inflammation in multiple sclerosis,
with PcTx1 protecting cells by reducing Ca2+ influx [14].
Thus, local tissue acidosis induced by cerebral ischemia
results in part from intracellular Ca2+ influx triggered by
ASIC activation [15]. Still another study maintains that
limiting ASIC1a expression after infarction exerts a neu-
roprotective effect [12]. Evidence shows that ASICs are
involved sensations of pain and taste [16].
Localization and electrophysiologic characteristics
of ASICs
In order to understand the physiologic functions of
ASICs, determining their distributions and electrophysio-
logic characteristics is critical. ASIC1a, ASIC1b, ASIC2a,
and ASIC3 activate and induce inward current at pH values
of 6.2, 5.9, 4.4, and 6.5, respectively [17]. In retinal ganglia,
a decline in synaptic cleft pH inhibits the opening of pre-
synaptic membrane Ca2+ channels. Changes in synaptic
cleft pH likely are important in activation of ASICs [18].Fig. 1 Biophysical properties of ASICs: representative current traces for ASIC
potential fixed at -60 mV)ASIC1a is expressed at synapses, primarily in conjunction
with the postsynaptic membrane [19]. Knock out of
ASIC1a inhibits pH 5.0-induced inward current in cultured
neurons from hippocampus, amygdala, and cortex [20].
ASIC1a is also co-expressed with ASIC1b in sensory neu-
rons [21]. The ASIC2b subunit, which by itself is nonfunc-
tional, is chiefly expressed in neurons of outer peripheral
and central nervous systems, whereas ASIC3 is largely
expressed in dorsal root ganglia (DRG) [22]. Other re-
searchers have demonstrated expression of ASIC3 in bone,
muscle, and cardiac tissue and expression of ASIC4 in pi-
tuitary gland [21, 23].
Pharmacologic characteristics of ASICs
Amiloride, which is widely used clinically as a diuretic,
inhibits Na+ channels in renal tubular epithelial cells and
is a non-specific inhibitor of ASICs [11]. With an IC50
of ~10-50 μM, amiloride not only suppresses ASIC cur-
rents but also prevents upsurges of intracellular Ca2+
and plasma membrane depolarization induced by extracel-
lular acidosis. Studies of the Na+ ion channel family indi-
cate that amiloride directly blocks ASIC activation, thereby
inhibiting current generated via acidic pH levels [24].
A-317567 is a small molecule (reportedly more select-
ive than amiloride) and a nondiscriminatory inhibitor of
ASIC currents in sensory and central neurons capable of
blocking ASIC1a, ASIC2a, and ASIC3 currents [25]. Un-
like amiloride, A-317567 provides significant relief from
chronic pain induced by tissue acidification [25].
Latest studies also suggest that non-steroidal anti-
inflammatory drugs (NSAIDs) help relieve pain by
modulating ASIC activity [26]. NSAIDs directly inhibit
inflammation-related sensory neuronal increases in ex-
pression and activity of ASIC1a and ASIC3, thus confer-
ring their analgesic effect [27, 28].
Tarantula toxin 1 (psalmotoxin, PcTx1) is another se-
lective inhibitor of ASIC1a [29]. In a heterologous ex-
pression system, PcTx1 inhibits ASIC1a-induced current
(IC50 ~ 1 nM), with no inhibitory effect on currents1a, ASIC2a, and ASIC3 at pH 6.0, 4.5, and 5.0, respectively (membrane
Fig. 2 ASICs are activated by extracellular protons (H+) and are primarily permeable to Na+ (Ca2+ to a lesser degree). ASIC activation depolarizes
cell membranes, activating voltage-gated Ca2+ channels (VGCCs) and N-methyl-D-aspartate receptors (NMDARs) to induce influx of Ca2+. Ca2+
influx contributes to calmodulin-dependent protein kinase II (CaMKII) phosphorylation and may influence other second-messenger pathways.
Amiloride, NSAIDs, and nafamostat are ASIC inhibitors
Liu et al. Translational Neurodegeneration  (2015) 4:10 Page 3 of 8induced by voltage-gated ion channels, including some
K+, Na+, and Ca2+ channels, and ligand-gated channels
[30]. At this concentration, PcTx1 changes the affinity of
ASIC1a for H+ ions, transforming the channels from
resting to inactivated states and increasing their closing
times [30, 31].
APETx2 is a selective inhibitor of ASIC3 [32]. Declin-
ing extracellular pH triggers a biphasic ASIC3 response:
fast depolarization followed by a prolonged refractory
period. APETx2 inhibits several subunits (i.e., 1a, 1b, 2b)
of ASIC3 but does not affect ASIC1a, ASIC1b, ASIC2a,
or ASIC3/2a [33]. APETx2 inhibits ASIC3-generated
and sustained window currents evoked at pH 7.0 [34].
The Texas coral snake toxin known as MitTx activates
ASIC1a and ASIC1b homomers and enhances pH sensi-
tivity of ASIC2a channels [35]. MitTx has weak effects
on ASIC2a if applied at pH 7.4 but potentiates acid-
evoked current by shifting the activation curve towards
less acidity. The effect of MitTx on ASIC-mediated neur-
onal currents in trigeminal ganglia of mice is a function of
ASIC1a channels and is abolished in ASIC1a-knockout
mice [36].Another agent, 2-guanidine-4-methylquinazoline (GMQ),
acts to persistently activate ASIC3 at normal pH [37]. Injec-
tion of GMQ into a mouse paw activates ASIC3, triggering
pain behavior in wild-type but not in ASIC3-knockout
mice. Although the potency of GMQ in activating ASIC3 is
low (EC50 ~ 1 mM) at physiologic Ca2+ concentrations,
GMQ may influence pH dependencies of other ASIC sub-
types, preempting current at physiologic pH by a shift to
more acidic pH [2].
PhcrTx1 is a compound extracted from the sea anem-
one (Phymanthus crucifer) that inhibits peak neuronal
ASIC currents in rat DRG [38].
Endogenous compounds that are active in this setting
include spermine, which intensifies ASIC1a activation and
aggravates ischemic neuronal injury [39], and agmatine,
which activates homomeric ASIC3 and heteromeric
ASIC3-ASIC1b [37, 40]. Mambalgin-1, a peptide isolate of
snake venom, selectively inhibits currents mediated by
ASIC1and ASIC1b homomers and heteromers [41]. The
potent protease inhibitor, nafamostat, is used to treat acute
pancreatitis [42]. It also inhibits ASIC1a and ASIC2a and
blocks initial-phase transient currents of ASIC3 [43].
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neurologic diseases
The various functions of ASICs in the nervous system have
yet to be fully understood. ASICs are widely distributed
throughout all regions of the brain where they participate
in synaptic plasticity, learning, and sensory transduction. In
particular, ASIC1a is a known purveyor of synaptic plasti-
city, especially the facilitation of N-methyl-D-aspartate
(NMDA) receptor activation in long-term potentiation
(LTP) of hippocampus [44]. However, a recent study by
the Lien group showed that disruption of the ASIC1a gene
did not impair normal hippocampal LTP and spatial
memory in ASIC1a conditional knockout mice [45]. Still,
Wemmie et al. recently detected local pH changes during
normal brain activity in mouse and human brains, under-
scoring the potential for ASIC activation in this context
[46]. More studies are clearly needed to delineate the roles
of ASIC1 in the nervous system (Table 2).
Parkinson’s disease
Parkinson’s disease (PD) is a disabling disease character-
ized by selective, gradual apoptosis of midbrain dopamin-
ergic (DA) neurons and progressive motor deterioration.
Increasing efforts have been made to identify putative
causes of PD, namely oxidative stress, microglial inflam-
mation, and mitochondrial dysfunction. Interestingly,
these processes often result in tissue acidification; and lac-
tic acidosis, which further aggravates neuronal damage,Table 2 ASICs in neurologic disorders
Disease Role of ASICs
Parkinson’s
disease
Lactic acidosis occurs in the brains of patients with PD.
Amiloride helps protect against substantia nigra neurona
Parkin gene mutations result in abnormal ASIC currents.
Huntington’s
disease
ASIC1 inhibition enhances ubiquitin-proteasome system
Pain ASIC3 is involved in: 1) primary afferent gastrointestinal v
system, and 3) mechanical nociception of the colon.
Blocking neuronal ASIC1a expression in dorsal root gang
NSAIDs inhibit sensory neuronal ASIC expression.
Cerebral ischemia Neuronal ASIC2 expression in the hypothalamus is upreg
Blockade of ASIC1a exerts a neuroprotective effect in a m
Migraine Most dural afferent nerves express ASICs.
Multiple sclerosis ASIC1a is upregulated in oligodendrocytes and in axons
brain tissue from patients with multiple sclerosis.
Blockade of ASIC1a may attenuate myelin and neuronal
Seizure Intraventricular injection of PcTX-1 increases the frequenc
Low-pH stimulation increases ASIC1a inhibitory neuronal
Malignant glioma ASIC1a is widely expressed in malignant glial cells.
PcTx1 or ASIC1a knock-down inhibits cell migration and
Amiloride analogue benzamil also produces cell-cycle arrhas been documented in the brains of patients with PD
and in the classic 1-methyl-4-phenyl-1,2,3,6-tetrahydro-
pyridine (MPTP)-induced animal model of PD [47, 48]. A
recently conducted study has demonstrated that mito-
chondrial ASIC1a may serve as an important regulator of
MPT pores, thus contributing to oxidative neuronal cell
death [49]. Moreover, Arias and colleagues have found
that MPTP-treated mice develop brain tissue acidosis and
that ASIC inhibitors amiloride and PcTx-1 protect against
substantia nigra neuronal degeneration by reducing levels
of DA and its transporter and preventing apoptosis [50].
In addition, mutation of the parkin gene or a lack of
endogenous parkin protein results in abnormal ASIC cur-
rents, protein degradation, and DA neuronal injury, sug-
gesting that ASIC currents may mediate the fundamental
pathology in PD [51]. ASIC inhibitors amiloride and PcTx-
1 are also protective of substantia nigra in the mouse PD
model, preventing neuronal loss and apoptosis [50]. Lipo-
polysaccharide (LPS) stimulation likewise increases levels of
ASIC1 and ASIC2a expression in rat microglia and induces
inflammatory cytokines [52]. Such findings collectively indi-
cate that modulating microglial ASIC function may control
neurodegenerative diseases such as PD.
Huntington’s disease
In individuals with Huntington’s disease (HD), CAG re-
peats of the huntingtin gene IT15 (copy number >35–40)
produce variations in the huntingtin protein, leading tol degeneration, inhibiting apoptosis.
activity and reduces huntingtin-polyglutamine accumulation.
isceral pain, 2) chemical nociception of the upper gastrointestinal
lia may confer analgesia.
ulated after ischemia.
iddle cerebral artery occlusion model.
of an acute autoimmune encephalomyelitis mouse model, as well as in
damage in multiple sclerosis.
y of tonic-clonic seizures.
currents.
cell-cycle progression in gliomas.
est in glioblastoma.
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form large aggregates in the brain, leading to disrupted
neuronal function and neuronal death. As yet, there is no
effective treatment. However, Wong et al. have reported
that ASIC1 inhibition enhances ubiquitin-proteasome sys-
tem activity and reduces huntingtin-polyglutamine accu-
mulation, implicating ASICs in the pathogenesis of HD as
well [53].
Pain
Tissue acidosis often increases pain sensitivity. Release
of H+ ions in damaged tissue lowers the pH locally, pro-
moting pain receptor depolarization and generating pain
[14]. Somatic pain originating in the peripheral nervous
system is attributable to ASIC3 [54]. This not only per-
tains to primary afferent gastrointestinal visceral pain
but also applies to chemical nociception of the upper
gastrointestinal system and to mechanical nociception of
the colon [55]. Hence, ASIC3 inhibition may be a means
of relieving chronic abdominal pain [56]. Analgesia may
similarly be achieved by blocking neuronal ASIC1a ex-
pression in DRG, so it appears that ASIC1a activation is
also a factor in sensitization of the peripheral nervous
system and generation of pain [56]. A-317567, an inhibitor
of ASIC1/3, alleviates skin pain in mice after surgery [56].
Additionally, NSAIDs may inhibit ASIC expression in sen-
sory neurons, block Ca2+ channels, and reduce peak ASIC
currents [28, 57]. Expression levels of ASIC1a and ASIC2a
are upregulated in the spinal cord, presumably to effect
central pain sensitization [58, 59]. Genetic disruption of
ASIC1a alleviates mechanical hyperalgesia elicited by
intrathecal brain-derived neurotrophic factor (BDNF) in-
jections [60], and intrathecal administration of PcTx-1
mitigates pain behavior in rodents [61]. These studies pro-
vide compelling evidence that inhibition of ASICs may
ease pain.
Cerebral ischemia
Severe cerebral ischemia may lower brain pH to 6.3 or
less, resulting in Ca2+ overload and neuronal cytotoxicity.
ASIC1a and ASIC2a are widely expressed in the central
nervous system [56]. Because ASIC1a is selectively perme-
able to Ca2+, activation of ASIC1a-bearing channels pro-
motes Ca2+ influx [4]. Activation of ASIC1a may trigger
membrane depolarization, spurring Ca2+ influx directly via
ASIC1a homomers or ASIC1a/2b heteromers, voltage-
gated Ca2+ channels, and NMDA receptors [62]. Intracellu-
lar Ca2+ overload then evokes a sequence of cytotoxic
events that ultimately aggravate tissue and cell damage
through intracellular enzyme activation. Cytotoxicity due to
acidic metabolites and intracellular Ca2+ overload causes
protein, lipid, and nucleic acid degradation, with apoptosis
and necrosis as eventual endpoints. Zhang et al. found that
ischemia has no effect on neuronal ASIC1 expression inthe hypothalamus but ASIC2 expression and expression of
anti-apoptotic proteins Bcl-2 and Bcl-W were upregulated
[63], so perhaps ASIC2 takes part in preventing apoptosis
induced by cerebral ischemia [63]. Nevertheless, other stud-
ies do show that ASIC1a blockade confers neuroprotective
effects in a middle cerebral artery occlusion model [39, 64].
Thus, the functional roles of ASICs may vary in differing
pathologic states, rendering them a new therapeutic target
in ischemic brain injury.
Migraine
Migraine is typically a severe unilateral or bilateral pulsa-
tile headache. Studies indicate that ASICs have major roles
in activating pain-sensitive afferent nerves during mi-
graines [65, 66], including dural branches [66]. Dural is-
chemia or release of macrophage granular contents may
cause local inflammatory changes, lowering tissue pH
locally and in turn activating ASICs and dural primary af-
ferent nerves [67]. Neuronal ASIC3 expression is found in
most trigeminal ganglia (TG) and dural afferents [68]. Cal-
citonin gene-related peptide (CGRP) release, resulting in
neurogenic inflammation and headache progression, is in-
creased in TG neurons via ASIC3 activation [68]. In a pre-
clinical study, amiloride was found to block cortical
spreading depression (CSD) and inhibit TG activation, im-
plying that an ASIC1-dependent mechanism is operant
[69]. ASIC signaling cascades then seem to be critical in
development of migraine, despite the need for greater
clarity at present.
Multiple sclerosis
ASIC1a is upregulated in oligodendrocytes and in axons
of an acute autoimmune encephalomyelitis mouse model,
as well as in brain tissue from patients with multiple scler-
osis, and this increased expression is associated with
axonal injury [70]. On the other hand, genetic disruption
of ASIC1 alleviates this axonal degeneration and reduces
clinical deficits [71]. In addition, amiloride attenuates
myelin and neuronal damage in multiple sclerosis [72].
Blockade of ASIC1a expression may therefore confer neu-
roprotective effects in patients with multiple sclerosis.
Seizure
During seizure activity, intense neuronal firing causes a
drop in brain pH, raising the possibility that abnormal
activation of ASICs affect onset and maintenance of epi-
leptic seizures. The frequency of tonic-clonic seizures is
increased by intraventricular injection of the ASIC1a in-
hibitor PcTX-1 [73]. However, EEG tracings confirm that
ASIC1a overexpression does not affect seizure onset and
may prematurely terminate episodes [74]. As opposed to
ASIC1a-knockout mice, wild-type mice show declines in
magnitude and intensity of seizures, indicating that a
drop in pH and augmented ASIC1a expression both
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interneuronal and excitatory pyramidal cell stimulation
increases ASIC1a inhibitory neuronal currents, suggest-
ing that ASIC1a may limit seizures by dampering neur-
onal excitability [75].
Malignant glioma
ASIC1a is widely expressed in malignant glial cells.
Amiloride- and PcTx1-sensitive cation currents have been
recorded in human glioblastoma [76], and PcTx1 or
ASIC1a knock-down inhibits cell migration and cell-cycle
progression in gliomas [77, 78]. ASIC1a inhibition leads to
cell-cycle arrest through upregulation of cyclin-dependent
kinase inhibitor protein expression and blockade of
growth factor phosphorylation cascades [77, 78]. The
amiloride analogue, benzamil, also produces cell-cycle ar-
rest in glioblastoma [77]. This body of evidence clearly
links ASIC1a activation with cellular growth and migra-
tion in malignant gliomas.
Conclusion
In this review, expression, localization, and mechanisms
(biochemical, physiologic, and pathophysiologic) of ASICs
are discussed. Based on a substantial body of research,
largely derived from animal models, their involvement in
various neurologic diseases seems certain. It is therefore
important to determine how this knowledge translates to
humans, given that ASIC-blocking drugs have may have
therapeutic potential in a spectrum of neurologic and psy-
chiatric disorders. Better understanding of related molecu-
lar mechanisms and signaling pathways will help clarify
the role of ASICs going forward.
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